Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2984 • 2018 ACR/ARHP Annual Meeting
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol Hitchon⁵, Louis Bessette⁶, Gilles Boire⁷, Carter Thorne⁸, Janet E. Pope⁹, Vivian P. Bykerk¹⁰, Edward C. Keystone¹¹, Diane Tin¹² and Glen Hazlewood¹³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³McGill University, Montreal, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Toronto, Newmarket, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Implementation of RA guidelines have improved remission outcomes in RA; nevertheless 45% of early RA participants do not achieve remission in the first year.…
Abstract Number: 623 • 2018 ACR/ARHP Annual Meeting
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
Sofia Pazmino¹, René Westhovens², Veerle Stouten¹, Johan Joly³, Kristien Van der Elst³, Diederik De Cock⁴ and Patrick Verschueren³, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: In the Care in early RA (CareRA) trial, COBRA Slim, a combination of methotrexate (MTX) with a moderate-dose prednisone step-down-bridge scheme, showed a positive…
Abstract Number: 2987 • 2018 ACR/ARHP Annual Meeting
RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
Julie Legrand¹, Thomas Kirchgesner¹, Tatiana Sokolova², Bruno Vande Berg¹ and Patrick Durez², ¹Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Remission is arguably the best and ultimate therapeutic goal in early rheumatoid arthritis (ERA). ERA patients (pts) who reach rapid and sustained remission are…
Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Aileen L. Pangan³, Alan Friedman³, Mohamed-Eslam Mohamed⁴, Su Chen⁴, Maureen Rischmueller⁵, Ricardo Blanco⁶, Ricardo M. Xavier⁷ and Vibeke Strand⁸, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., North chicago, IL, ⁵The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…
Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Mihaela Maruseac¹, Patrick Durez^2,3, Adrien Nzeusseu Toukap⁴ and Maria Stoenoiu⁵, ¹Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
Abstract Number: 2391 • 2017 ACR/ARHP Annual Meeting
Incidence of Infections in Early Arthritis
Meriem Kerbachi¹, Louis Bessette², Cristiano S. Moura³, Sasha Bernatsky⁴, Orit Schieir⁵, Susan J. Bartlett⁶, Carol A Hitchon⁷, Janet E. Pope⁸, Gilles Boire⁹, Boulos Haraoui¹⁰, Edward C. Keystone¹¹, Diane Tin¹², Carter Thorne¹³ and Vivian P. Bykerk¹⁴, ¹McGill University, Montreal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, ON, Canada, ⁶Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹¹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³University of Toronto, Newmarket, ON, Canada, ¹⁴2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Few studies have focused on analyzing infection risk in recent-onset rheumatoid arthritis (RA).The main objective of this study was to estimate the incidence of…
Abstract Number: 1369 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis
Kijun Lee¹, Jennifer Lee², Hong-Ki Min¹, Hae-Rim Kim³, Sang-Heon Lee⁴, Sung-Hwan Park⁵, Ji Hyeon Ju⁶ and Hoyoun Kim¹, ¹The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Konkuk University Medical Center, Seoul, Korea, Republic of (South), ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 2426 • 2017 ACR/ARHP Annual Meeting
Altered Frequencies of Circulating Follicullar T Helper Cell Counterparts and Their Subsets but Not of Peripheral Helper T Cells, Are Associated with Increased Circulating Plasmablasts in Seropositive Early RA Patients
Paula Fortea-Gordo¹, Lorena Valdeolivas-De Opazo¹, Laura Nuño², Alejandro Villalba¹, Paloma Sanchez-Mateos³, Amaya Puig-Kröger⁴, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁴Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: Follicular T helper (Tfh) cells are typically located in lymphoid organs where they promote B cell differentiation and function. Circulating CD4 T cells expressing…
Abstract Number: 1386 • 2017 ACR/ARHP Annual Meeting
Tenosynovitis in the Forefoot at Disease Presentation Is Specific for RA: Results from a Cross-Sectional MRI Study in Early Arthritis
Yousra J. Dakkak¹, Debbie M. Boeters², Annette H.M. van der Helm-van Mil² and M. Reijnierse³, ¹Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The foot is a preferential location for rheumatoid arthritis (RA)-manifestation, but physical examination of the metatarsophalangeal (MTP) joints is difficult. Magnetic Resonance Imaging (MRI)…
Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting
Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)
Arthur Kavanaugh¹, Ronald F van Vollenhoven², Prashanth Sunkureddi³, Ying Zhang⁴, Jessica L. Suboticki⁵ and Josef S. Smolen⁶, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Mettawa, IL, ⁶Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
Abstract Number: 1393 • 2017 ACR/ARHP Annual Meeting
Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis
Cheryl Barnabe¹, Orit Schieir², Glen Hazlewood¹, Susan J. Bartlett³, Carol A Hitchon⁴, Janet E. Pope⁵, Gilles Boire⁶, Edward C. Keystone⁷, Diane Tin⁸, B Haraoui⁹, Vivian P. Bykerk¹⁰ and Carter Thorne¹¹, ¹Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada
Background/Purpose: Outcomes in ERA are largely thought to reflect individual prognostic factors and treatment strategy employed. We hypothesize that an additional factor may be the…
Abstract Number: 2939 • 2017 ACR/ARHP Annual Meeting
Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis
Fan XIAO¹, JIANG YUE², Queenie Mak³, Lai-Shan Tam⁴ and James F Griffith⁵, ¹Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, HONG KONG, Hong Kong, ³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, HONGKONG, Hong Kong
Clinical Correlate of Synovial Proliferation in Early Rheumatoid Arthritis Background/Purpose: To determine whether semi-quantitative, quantitative assessment of synovitis severity or synovial perfusion data correlates best…
Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial
Yannick Degboé^1,2, Michael Schiff³, Michael Weinblatt⁴, Roy Fleischmann⁵, HA Ahmad⁶ and Arnaud Constantin^2,7, ¹Toulouse University Hospital, Toulouse, France, ²Université Paul Sabatier, Toulouse, France, ³University of Colorado, Denver, CO, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Purpan University Hospital, Toulouse, France
Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].